NR3C2 and hydrops fetalis: Another study analyzed whether the benefits of dapagliflozin were consistent in relation to background HF therapy (yes/no): mineralocorticoid receptor antagonist, sacubitril/valsartan, ivabradine, diuretic, digoxin, implanted cardioverter-defibrillating device, and cardiac resynchronization therapy and also according to the dose (≥50% and <50% of target dose): ACEi/ARB, beta blocker, mineralocorticoid receptor antagonist, showing that the benefit of dapagliflozin was independent of background HF therapy [64].